Table 2

Characteristics of patients with COPD at entry date to the cohort, stratified by medication group

CharacteristicsNRT
(N=10 426 )
Bupropion
(N=350)
Varenicline
(N=3574)
Age, mean (SD)55.53 (9.72)52.42 (9.31)52.48 (8.82)
Female sex5390 (51.70)165 (47.14)1822 (50.98)
MRC* score, mean (SD)2.37 (1.02)2.22 (0.96)2.23 (0.98)
Socioeconomic status†, mean (SD)3.28 (1.35)3.14 (1.31)3.20 (1.37)
Diabetes1163 (11.15)20 (5.71)325 (9.09)
Peptic ulcer disease819 (7.86)23 (6.57)236 (6.60)
Renal disease979 (9.39)14 (4.00)234 (6.55)
Rheumatological disease679 (6.51)13 (3.71)196 (5.48)
Cancer943 (9.04)29 (8.29)277 (7.75)
Alcohol misuse1112 (10.67)22 (6.29)297 (8.31)
Prior ischaemic heart disease1556 (14.92)32 (9.14)430 (12.03)
Prior stroke829 (7.95)22 (6.29)222 (6.21)
Prior heart failure315 (3.02)5 (1.43)68 (1.90)
Prior peripheral vascular disease416 (3.99)6 (1.71)109 (3.05)
Prior arrhythmia603 (5.78)13 (3.71)126 (3.53)
Prior depression4149 (39.79)132 (37.71)1264 (35.37)
Prior self-harm1174 (11.26)32 (9.14)357 (9.99)
  • Data are presented as N (percentage within drug group) unless stated otherwise.

  • *Medical Research Council dyspnoea score: 1 (lowest) to 5 (highest level of dyspnoea).20

  • †Townsend Index: 1 (lowest) to 5 (highest level of deprivation).24

  • NRT, nicotine replacement therapy.